Brachytherapy

Papers
(The median citation count of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
PPP03 Presentation Time: 10:48 AM39
BP02 Presentation Time: 4:09 PM26
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM21
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM18
PHSOR06 Presentation Time: 9:25 AM17
PO042516
PO032416
PPP02 Presentation Time: 10:39 AM15
MPP02 Presentation Time: 4:09 PM15
PO022715
BP08 Presentation Time: 5:03 PM15
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer14
PO041714
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data12
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study12
PO024912
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po11
GPP03  Presentation Time: 9:33 AM11
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications11
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy11
PO4710
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost10
PSOR12  Presentation Time: 5:25 PM10
PO3510
P010510
PO9310
Editorial Board10
PHSOP2  Presentation Time: 9:05 AM10
PSOR03  Presentation Time: 12:10 PM9
PL02 Presentation Time: 1:45 PM9
PO04219
Editorial Board9
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis9
MSOR11 Presentation Time: 8:50 AM9
PSOR8  Presentation Time: 12:05 PM9
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy9
PO02349
PPP04  Presentation Time: 10:57 AM8
Author Index8
Determination of the optimal time for planning SAVI brachytherapy for APBI8
P03018
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy8
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma8
PRPP05  Presentation Time: 11:06 AM8
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
MSOR12 Presentation Time: 8:55 AM7
PP05  Presentation Time: 5:06 PM7
Masthead7
PL02  Presentation Time: 1:45 PM7
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life7
PSOR02  Presentation Time: 4:35 PM7
PO207
Masthead7
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement7
PO217
GSOR14  Presentation Time: 11:35 AM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
PHSOR04  Presentation Time: 12:45 PM6
Partial breast irradiation: An updated consensus statement from the American brachytherapy society6
PO106
Table of Contents6
MSPP03  Presentation Time: 4:20 PM6
GSOR04  Presentation Time: 12:15 PM6
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes6
High-dose-rate brachytherapy for airway malignancy a single institution experience6
PO46  Presentation Time: 4:45 PM6
PP02  Presentation Time: 9:10 AM6
PHSOR05  Presentation Time: 12:50 PM6
The case for risk-stratified IORT for early breast cancer6
Table of Contents6
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM6
PO02415
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
PO04245
PO02425
PHSOR06  Presentation Time: 12:55 PM5
PO01095
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma5
PO1145
Skin Posters PO07015
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT5
PO155
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
PSOR02 Presentation Time: 11:35 AM5
PO01195
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle5
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM5
PO02614
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer4
GSOR09 Presentation Time: 12:10 PM4
MSOP06  Presentation Time: 8:25 AM4
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
GSOR13  Presentation Time: 12:30 PM4
GPP06  Presentation Time: 11:15 AM4
Editorial Board4
PO914
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology4
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM4
PPP05 Presentation Time: 11:06 AM4
Is single implant and multiple fractions radio-biologically iso-effective for cervical cancer high-dose-rate brachytherapy: Observation from patient cohorts during COVID pandemic4
Development of a dosimetric phantom using OSLDs or TLD-100 for external audits of high-dose-rate 192Ir brachytherapy sources: Preliminary results4
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
PO194
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
MSOP03  Presentation Time: 8:10 AM4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
PO02204
PO03204
PO01104
Improving complex brachytherapy efficiency: Multidisciplinary quality assurance and workflow optimization4
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal4
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation4
MPP02  Presentation Time: 4:09 PM4
PP02  Presentation Time: 10:09 AM4
Comment on “high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement”4
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review4
MSOR11 Presentation Time: 5:50 PM4
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
PO533
PSOR7  Presentation Time: 12:00 PM3
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
GPP04  Presentation Time: 9:42 AM3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PP05  Presentation Time: 11:36 AM3
Effect of radiation dosage to vital ocular structures on visual outcomes: Re-evaluation for the future3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Patterns of anesthesia(AS) and analgesia(AG) practice in gynecological brachytherapy in India3
PP04  Presentation Time: 9:47 AM3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
PSOR3  Presentation Time: 11:40 AM3
PRSOP03  Presentation Time: 11:40 AM3
P03043
PO40  Presentation Time: 4:45 PM3
PO523
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy3
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms3
Development of a phantom and analysis of brachytherapy dosimetry using the sulfamic acid/electron paramagnetic resonance system3
PRSOP08  Presentation Time: 12:05 PM3
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
PRPP02  Presentation Time: 10:39 AM3
PO33  Presentation Time: 10:30 AM3
PO863
MSOR9 Presentation Time: 5:40 PM3
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Table of Contents2
PL03 Presentation Time: 2:00 PM2
GSOR10 Presentation Time: 12:15 PM2
GSOR06 Presentation Time: 5:25 PM2
PO02582
PO03102
PO492
PO1122
MSPP05  Presentation Time: 4:40 PM2
GSOR20  Presentation Time: 12:05 PM2
PHSOP6  Presentation Time: 9:25 AM2
PP02  Presentation Time: 8:29 AM2
PO822
GYN Posters PO012
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
Table of Contents2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
PSOR06  Presentation Time: 12:25 PM2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
PO122
GSOR06  Presentation Time: 11:55 AM2
PP04  Presentation Time: 11:27 AM2
PO01112
Systematic review of brachytherapy for symptom palliation2
P01142
PO04082
PO02332
Masthead2
MSOR7 Presentation Time: 5:30 PM2
PO322
GSOR23  Presentation Time: 12:20 PM2
PHSOR08  Presentation Time: 1:05 PM2
PL04  Presentation Time: 2:15 PM2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
Actinium-225 Targeted Agents: Where Are We Now?2
PO042
MPP05  Presentation Time: 4:36 PM2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
PO04282
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
GSOR02  Presentation Time: 11:35 AM2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
GSOR12 Presentation Time: 5:55 PM2
PO03112
PO02292
Masthead2
PO03142
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
PO27  Presentation Time: 7:40 AM2
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
MSS11  Presentation Time: 4:35 PM2
Accelerated partial breast irradiation with high-dose-rate multicatheter brachytherapy: 30-year results of a phase 2 clinical trial2
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
PO102
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Table of Contents2
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer1
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
PO051
GPP06  Presentation Time: 10:00 AM1
PO1031
PO1021
PO1061
PO061
Table of Contents1
PPP01  Presentation Time: 4:00 PM1
PO1191
Sunday, June 19, 2022 10:30 AM - 11:30 AMPP07  Presentation Time: 10:30 AM1
PO28  Presentation Time: 7:40 AM1
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
P01171
Masthead1
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
PO901
GSOR05  Presentation Time: 12:20 PM1
PO191
GPP02  Presentation Time: 9:24 AM1
P01061
Brachytherapy outcome modeling in cervical cancer patients: A predictive machine learning study on patient-specific clinical, physical and dosimetric parameters1
PO1001
MSS04  Presentation Time: 4:00 PM1
PO131
PO171
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-1031
Therapeutic and prophylactic effects of radiation therapy in the management of recurrent granulation tissue induced tracheal stenosis: a review on the role of Endobronchial brachytherapy and external 1
PO271
MSOR7  Presentation Time: 5:15 PM1
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
PO111
Masthead1
Re: Letter to the editor with regards to “Impact of detector selection on commissioning of Leipzig surface applicators with improving immobilization in high-dose-rate brachytherapy” by Li et al.1
0.10367894172668